| 000 | 01072 am a22002413u 4500 | ||
|---|---|---|---|
| 042 | _adc | ||
| 100 | 1 | 0 |
_aHowes, Oliver D _eauthor _91606 |
| 700 | 1 | 0 |
_aBarnes, Thomas _eauthor _91607 |
| 700 | 1 | 0 |
_aLennox, Belinda _eauthor _91608 |
| 700 | 1 | 0 |
_aMarkham, Sarah _eauthor _91609 |
| 700 | 1 | 0 |
_aNatesan, Sridhar _eauthor _91610 |
| 245 | 0 | 0 | _aTime to re-evaluate the risks and benefits of valproate and a call for action |
| 260 | _c2022-12. | ||
| 500 | _a/pmc/articles/PMC7613842/ | ||
| 500 | _a/pubmed/35795925 | ||
| 520 | _aValproate is widely used in psychiatry and neurology, including off-label use. Here we consider its potential benefits and risks, particularly in women of child-bearing potential, and the evidence that clinical guidelines are adhered to. Finally, we consider the implications for clinical practice and research into its efficacy in off-label indications. | ||
| 540 | _a | ||
| 546 | _aen | ||
| 690 | _aArticle | ||
| 655 | 7 |
_aText _2local |
|
| 786 | 0 | _nBr J Psychiatry | |
| 856 | 4 | 1 |
_uhttp://dx.doi.org/10.1192/bjp.2022.94 _zConnect to this object online. |
| 999 |
_c1836 _d1836 |
||